ABSK021 for untreated advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new drug called ABSK021 for people with advanced pancreatic cancer who have not received any prior treatment. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your pancreatic cancer is advanced and cannot be removed by surgery, or has spread to other parts of the body.
- You have not had any prior chemotherapy or other systemic treatment for your pancreatic cancer.
- You are able to perform daily activities with mild or no help (ECOG score 0-2).
- You have no serious infections, heart problems, or other cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment approach for advanced pancreatic cancer in patients who have never received chemotherapy for their advanced disease. The trial aims to evaluate whether this new strategy can help control the cancer and improve outcomes.
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
This trial tests a combination of three drugs—capecitabine (a chemotherapy pill), camrelizumab (an immunotherapy), and apatinib (a targeted therapy)—for people with advanced pancreatic cancer whose previous treatment stopped working or who cannot tolerate standard chemotherapy.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
This trial tests a new drug called ABSK131 in people whose cancer has a missing MTAP gene. It is for advanced solid tumors that have not responded to standard treatments.
Hear when a new Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.